2017 Press Releases

Home»2017 Press Releases
30 08, 2017

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences

2017-08-30T15:19:09+00:00

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences PALO ALTO, Calif. – August 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two upcoming meetings [...]

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences2017-08-30T15:19:09+00:00
14 08, 2017

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results

2017-08-14T19:09:14+00:00

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results - Five Phase 2 Programs Advancing in Multiple Orphan Indications - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., August 14, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for [...]

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results2017-08-14T19:09:14+00:00
8 08, 2017

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th

2017-08-08T12:00:07+00:00

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th PALO ALTO, Calif. – August 8, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update [...]

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th2017-08-08T12:00:07+00:00
27 07, 2017

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

2017-07-27T15:06:44+00:00

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PALO ALTO, Calif., July 27, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for [...]

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection2017-07-27T15:06:44+00:00
24 07, 2017

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

2017-07-24T12:02:26+00:00

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif., July 24, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of enrollment [...]

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection2017-07-24T12:02:26+00:00
29 06, 2017

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals

2017-06-30T18:22:25+00:00

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals PALO ALTO and SAN DIEGO, Calif., June 29, 2017, Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a).  Financial terms of the agreement include a total upfront of $3.1 million in [...]

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals2017-06-30T18:22:25+00:00
14 06, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors

2017-06-14T16:56:31+00:00

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors - Company Prepares to Advance Orphan Disease Pipeline PALO ALTO, Calif., June 14, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, [...]

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors2017-06-14T16:56:31+00:00
12 06, 2017

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego

2017-06-12T14:46:00+00:00

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego - Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted PALO ALTO, Calif., June 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for [...]

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego2017-06-12T14:46:00+00:00
6 06, 2017

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients

2017-06-06T13:20:42+00:00

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients PALO ALTO, Calif., June 6, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion of enrollment of the Phase 2 multiple-ascending dose (MAD) study evaluating subcutaneous (SC) exendin [...]

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients2017-06-06T13:20:42+00:00
30 05, 2017

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th

2017-05-30T12:02:59+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th PALO ALTO, Calif. – May 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at [...]

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th2017-05-30T12:02:59+00:00